About us
Inicure AB is a spinoff from the autoimmunity-focused company Pronoxis AB.
The company is developing anti-infectious assets activating the formyl peptide receptor-1 (FPR1) and was founded in 2024 by Peter Olofsson-Sahl, Sara Malcus, Johan Bylund, and GU Ventures AB.
Team
Peter Olofsson-Sahl
Preclinical drug development and international project management, founder of several innovative research companies
Sara Malcus
Business development and investment management. Extensive experience in the management of life science start-up companies, from CEO and Board positions.
Johan Bylund
Immunology and infections, including targeting of immunological mechanisms
Partners
Academic collaborators
NATIONWIDE CHILDREN’S HOSPITAL- Kidney and Urinary Tract Research Center
In a research collaboration with Dr. Juan de Dios Ruiz-Rosado and Dr. Brian Becknell within the Kidney and Urinary Tract Research Center at Nationwide Children’s Hospital, Columbus Ohio – we are jointly studying the immunological mechanism of the role of NOX inhibition as a mechanism for treatment of diseases of the kidney and urinary tract.
In this research project led by Dr. Juan de Dios Ruiz-Rosado, we are exploring the potential anti-bacterial properties of Pronoxis FPR specific agonists as potential novel agents to treat urinary tract infections (UTI).
UNIVERSITY OF GOTHENBURG – Dept. of Oral Microbiology & Immunology
The research activities at the department of oral microbiology & immunology involve studies on microorganisms present in the oral cavity and their interactions with the immune system. Furthermore, immune function in health and during oral diseases is studied.
In a collaboration with Professor Johan Bylund, we are studying the Inicure compounds and how they affect neutrophil function.
SWANSEA UNIVERSITY -Medicine, health and life science
In a research collaboration with Dr Heather Chick and Professor Helen Griffiths at the faculty of Medicine, Health and Life science, Swansea University – we are jointly studying the role of FPR/NOX2 activation as a new way to combat and treat infections.
In this collaborative research project (also part of the EU-funded project Neutrocure), we are exploring the anti-bacterial properties of Inicures’ FPR1 agonists, validating their anti-infective effects using in vitro cell models.